Predicting Clinical Dementia Rating Using Blood RNA Levels

Area of Science:

• Neuroscience
• Genomics
• Biomarker Discovery

Background:

• The Clinical Dementia Rating (CDR) is a standard measure for cognitive decline in Alzheimer's disease (AD).
• The Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset provides valuable data for AD research.
• Blood-based biomarkers offer a less invasive approach for diagnosing neurodegenerative diseases.

Purpose of the Study:

• To investigate the predictive power of blood RNA levels for cognitive status in Alzheimer's disease.
• To determine if machine learning can identify patterns in blood RNA for classifying cognitive impairment.
• To explore the potential of combining non-individually significant RNA markers for improved diagnostic accuracy.

Main Methods:

• Utilized blood microarray data from 741 ADNI participants categorized by CDR (0, 0.5, ≥1.0).
• Employed machine learning algorithms to predict cognitive status based solely on blood RNA levels.
• Analyzed individual probe significance and combined suggestive, non-significant probes for predictive modeling.

Main Results:

• A single probe for chloride intracellular channel 1 (CLIC1) was significant after correction, but insufficient alone.
• Combining individually non-significant RNA probes achieved an average predictive accuracy of 87.87% for classifying cognitive groups.
• The best model demonstrated high performance with precision of 0.902, recall of 0.895, and ROC area of 0.904.

Conclusions:

• Blood RNA levels, particularly when analyzed collectively using machine learning, show significant potential for predicting cognitive status in Alzheimer's disease.
• While CLIC1 alone is not a reliable biomarker, combinations of subtle RNA signals may enhance diagnostic accuracy.
• Machine learning can uncover complex interactions among non-individually predictive features, contributing to a better understanding of cognitive decline.